CL2016002683A1 - Proteínas agonistas de los receptores de trail de cadena simple - Google Patents

Proteínas agonistas de los receptores de trail de cadena simple

Info

Publication number
CL2016002683A1
CL2016002683A1 CL2016002683A CL2016002683A CL2016002683A1 CL 2016002683 A1 CL2016002683 A1 CL 2016002683A1 CL 2016002683 A CL2016002683 A CL 2016002683A CL 2016002683 A CL2016002683 A CL 2016002683A CL 2016002683 A1 CL2016002683 A1 CL 2016002683A1
Authority
CL
Chile
Prior art keywords
receptor agonist
agonist proteins
single chain
trail receptor
trail
Prior art date
Application number
CL2016002683A
Other languages
English (en)
Inventor
Oliver Hill
Christian Gieffers
Meinolf Thiemann
Fritz G Buchanan
Darren C Phillips
Susan E Lappe
Original Assignee
Abbvie Inc
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Apogenix Ag filed Critical Abbvie Inc
Publication of CL2016002683A1 publication Critical patent/CL2016002683A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)

Abstract

<p>Proteínas específicas que son agonistas de los receptores de TRAIL. Ácidos nucleicos que las codifican. Métodos para tratar una enfermedad o un trastorno asociado a los TRAIL en un sujeto. Las proteínas agonistas de los receptores de TRAIL que se proveen en la presente comprenden tres dominios de TRAIL solubles y un fragmento Fc. Las proteínas agonistas de los receptores de TRAIL no forman agregados de manera sustancial y son apropiadas para aplicaciones terapéuticas, de diagnóstico y/o de investigación.</p>
CL2016002683A 2014-04-23 2016-10-21 Proteínas agonistas de los receptores de trail de cadena simple CL2016002683A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
CL2016002683A1 true CL2016002683A1 (es) 2017-07-07

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002683A CL2016002683A1 (es) 2014-04-23 2016-10-21 Proteínas agonistas de los receptores de trail de cadena simple

Country Status (37)

Country Link
US (4) US9908927B2 (es)
EP (2) EP3134430B1 (es)
JP (2) JP6523331B2 (es)
KR (2) KR102079919B1 (es)
CN (2) CN111718424A (es)
AR (1) AR100168A1 (es)
AU (3) AU2015249649B2 (es)
BR (1) BR112016024515B1 (es)
CA (2) CA2946402C (es)
CL (1) CL2016002683A1 (es)
CR (1) CR20160516A (es)
CY (1) CY1120281T1 (es)
DK (1) DK3134430T3 (es)
DO (1) DOP2016000284A (es)
EC (1) ECSP16089579A (es)
ES (1) ES2672368T3 (es)
HR (1) HRP20180950T1 (es)
HU (1) HUE038914T2 (es)
IL (2) IL248244B (es)
LT (1) LT3134430T (es)
MA (2) MA39770A (es)
MX (2) MX2016013858A (es)
MY (1) MY181986A (es)
NO (1) NO2776305T3 (es)
PE (1) PE20170299A1 (es)
PH (1) PH12016502079B1 (es)
PL (1) PL3134430T3 (es)
PT (1) PT3134430T (es)
RS (1) RS57153B1 (es)
RU (1) RU2699285C2 (es)
SG (3) SG10202111785VA (es)
SI (1) SI3134430T1 (es)
TR (1) TR201806912T4 (es)
TW (2) TWI747178B (es)
UA (1) UA118286C2 (es)
UY (1) UY36095A (es)
WO (1) WO2015164588A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170138585A (ko) 2015-05-04 2017-12-15 아포게닉스 아게 단일-쇄 cd40-수용체 작용제 단백질
EP3365361A1 (en) 2015-10-23 2018-08-29 Apogenix AG Single-chain light receptor agonist proteins
AU2016341402B2 (en) * 2015-10-23 2020-08-27 Apogenix Ag Single-chain GITR-receptor agonist proteins
AU2016341409B2 (en) 2015-10-23 2021-02-25 Apogenix Ag Single-chain CD27-receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
JP7091248B2 (ja) * 2016-03-01 2022-06-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 低減されたｌ－グルタミナーゼ活性および増強された安定性を有するｌ－アスパラギナーゼ変異体および融合タンパク質
MX2018011219A (es) * 2016-03-16 2019-01-10 Merrimack Pharmaceuticals Inc Trail diseñado por ingenieria para terapia de cancer.
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US20190185541A1 (en) * 2016-06-13 2019-06-20 Merrimack Pharmaceuticals, Inc. Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
US11578315B2 (en) 2017-08-11 2023-02-14 The Board Of Trustees Of The University Of Illinois Truncated guinea pig L-asparaginase variants and methods of use
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019178438A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
WO2021229103A2 (en) 2020-05-15 2021-11-18 Apogenix Ag Multi-specific immune modulators
WO2022248662A1 (en) 2021-05-28 2022-12-01 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
PL393178A1 (pl) 2000-12-07 2011-02-14 Eli Lilly And Company Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulino-niezależną i kompozycja farmaceutyczna do leczenia pacjentów z otyłością
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7538088B2 (en) 2002-04-26 2009-05-26 California Institute Of Technology Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
EP1871798B1 (en) 2005-04-15 2009-10-14 Rappaport Family Institute For Research in the Medical Sciences Molecules and methods of using same for treating mcp-1/ccr2 associated diseases
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
EP3072903B1 (en) 2007-07-10 2017-10-25 Apogenix AG Tnf superfamily collectin fusion proteins
MX2010013239A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
US8450460B2 (en) * 2008-07-21 2013-05-28 Apogenix Gmbh Single-chain TNFSF fusion polypeptides
CA2737280A1 (en) 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
EP2379585A2 (en) * 2008-10-10 2011-10-26 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
CA2750533A1 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
CN102939303A (zh) 2009-12-22 2013-02-20 诺瓦提斯公司 四价cd47-抗体恒定区融合蛋白用于治疗
WO2011130324A1 (en) * 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
US9764038B2 (en) * 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
SG11201500134QA (en) 2012-07-18 2015-03-30 Apogenix Gmbh Composition comprising a mixture of cd95-fc isoforms

Also Published As

Publication number Publication date
PL3134430T3 (pl) 2018-08-31
UY36095A (es) 2015-10-30
MY181986A (en) 2021-01-18
US20180222962A1 (en) 2018-08-09
PH12016502079A1 (en) 2016-12-19
EP3134430B1 (en) 2018-03-21
KR102079919B1 (ko) 2020-02-24
RU2699285C2 (ru) 2019-09-04
NZ725476A (en) 2023-09-29
SG10201806465TA (en) 2018-08-30
TWI683825B (zh) 2020-02-01
KR20170012257A (ko) 2017-02-02
JP6523331B2 (ja) 2019-05-29
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
JP6714751B2 (ja) 2020-06-24
NO2776305T3 (es) 2018-01-27
US9908927B2 (en) 2018-03-06
PE20170299A1 (es) 2017-05-06
CR20160516A (es) 2017-05-10
US20210040178A1 (en) 2021-02-11
AU2020202247A1 (en) 2020-04-23
RU2016145608A (ru) 2018-05-28
MA39770A (fr) 2015-10-29
DK3134430T3 (en) 2018-05-22
UA118286C2 (uk) 2018-12-26
MX2016013858A (es) 2017-08-02
TR201806912T4 (tr) 2018-06-21
KR20190135546A (ko) 2019-12-06
PT3134430T (pt) 2018-04-20
PH12016502079B1 (en) 2016-12-19
AU2018271369A1 (en) 2018-12-20
ES2672368T3 (es) 2018-06-14
CA2946402C (en) 2023-02-28
HUE038914T2 (hu) 2018-12-28
EP3134430A1 (en) 2017-03-01
SI3134430T1 (en) 2018-05-31
AU2015249649B2 (en) 2018-10-04
BR112016024515B1 (pt) 2020-03-31
CY1120281T1 (el) 2019-07-10
US20150337027A1 (en) 2015-11-26
MA45069A (fr) 2019-04-03
JP2019162114A (ja) 2019-09-26
EP3366699A1 (en) 2018-08-29
TW201620928A (zh) 2016-06-16
IL248244B (en) 2020-03-31
TWI747178B (zh) 2021-11-21
RU2016145608A3 (es) 2018-12-26
IL248244A0 (en) 2016-11-30
CN106459221B (zh) 2020-09-01
ECSP16089579A (es) 2018-05-31
JP2017513503A (ja) 2017-06-01
TW202024123A (zh) 2020-07-01
SG11201608767XA (en) 2016-11-29
LT3134430T (lt) 2018-05-10
IL272612A (en) 2020-03-31
AU2015249649A1 (en) 2016-11-10
RS57153B1 (sr) 2018-07-31
WO2015164588A1 (en) 2015-10-29
HRP20180950T1 (hr) 2018-08-10
CA2946402A1 (en) 2015-10-29
AR100168A1 (es) 2016-09-14
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
SG10202111785VA (en) 2021-12-30
MX2019013587A (es) 2020-01-13
DOP2016000284A (es) 2017-02-15
BR112016024515A2 (pt) 2017-10-10
US20240174731A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
CL2016002683A1 (es) Proteínas agonistas de los receptores de trail de cadena simple
CL2018003406A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CY1119098T1 (el) Αγωνιστες fgfr1 και μεθοδοι χρησης
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
PE20181349A1 (es) Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
CL2015002654A1 (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
DK3134123T3 (da) Il-2r-beta-selektive agonister i kombination med et anti-ctla-4-antistof eller et anti-pd-1-antistof
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CL2015002734A1 (es) Heterociclos tricíclicos como inhibidores de la proteína bet.
PE20160870A1 (es) Anticuerpos anti-claudina novedosos y metodos de uso
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
DOP2018000138A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
CU24427B1 (es) Moléculas de anticuerpo que se unen a tim-3
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
EA201591059A1 (ru) МОДУЛЯТОРЫ СИРОТСКИХ ГАММА-РЕЦЕПТОРОВ РЕТИНОИДОВ (RORγ) ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
BR112017009517A2 (pt) receptores de antígeno quimérico anti-cldn e métodos de uso
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
CO2017003005A2 (es) Anticuerpos anti-mfi2
CO7240399A2 (es) Proteínas fijadoras de antígeno antagonistas del receptor de acción dual y sus usos
BR112017023131A2 (pt) anticorpos anti- fcrn
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn